ConductScience.org, home

Paper17554384

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

Kohl TM and 6 others. Leukemia, 2007. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Papers, record 17554384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17554384

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
PubMed
Journal
Leukemia
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
1.72
iCite
Revised in PubMed
2026-10-10
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kohl TMT M
2Hellinger CC
3Ahmed FF
4Buske CC
5Hiddemann WW
6Bohlander SKS K
7Spiekermann KK

Source PubMed

Download CSV of authors

Topics29

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biphenyl CompoundsMajor topic
Drug Resistance, NeoplasmMajor topic
Leukemia, MyeloidMajor topic
NitrophenolsMajor topic
Proto-Oncogene Proteins c-bcl-2Major topic
SulfonamidesMajor topic
fms-Like Tyrosine Kinase 3Major topic
Acute Disease
Adult
Aged
Aged, 80 and over
Apoptosis
Blotting, Western
Cell Proliferation
Cells, Cultured
Flow Cytometry
Humans
Karyotyping
Middle Aged
Molecular Mimicry
Myeloid Cell Leukemia Sequence 1 Protein
Neoplasm Proteins
Peptide Fragments
Piperazines
Proto-Oncogene Proteins
STAT5 Transcription Factor
Signal Transduction
Trans-Activators
bcl-X Protein

Source PubMed

Download CSV of topics

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112124170Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.Cancer Cell2002https://conductscience.org/library/papers/12124170PubMed
29525737Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.Oncogene1998https://conductscience.org/library/papers/9525737PubMed
314654525An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.Clin Cancer Res2003https://conductscience.org/library/papers/14654525PubMed
415626746Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.Blood2005https://conductscience.org/library/papers/15626746PubMed
511146161Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.Exp Hematol2000https://conductscience.org/library/papers/11146161PubMed
616166262miR-15 and miR-16 induce apoptosis by targeting BCL2.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16166262PubMed
715902208An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature2005https://conductscience.org/library/papers/15902208PubMed
817234790Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.Cancer Res2007https://conductscience.org/library/papers/17234790PubMed
98943060The AML1/ETO fusion protein activates transcription of BCL-2.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8943060PubMed
1016997913Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16997913PubMed
1112842996Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.Blood2003https://conductscience.org/library/papers/12842996PubMed
1212951584The role of FLT3 in haematopoietic malignancies.Nat Rev Cancer2003https://conductscience.org/library/papers/12951584PubMed
1317097561The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.Cancer Cell2006https://conductscience.org/library/papers/17097561PubMed
1416556074MicroRNAs as a potential magic bullet in cancer.Future Oncol2006https://conductscience.org/library/papers/16556074PubMed
1512406902The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.Blood2003https://conductscience.org/library/papers/12406902PubMed
1615901672Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.Genes Dev2005https://conductscience.org/library/papers/15901672PubMed
1712890867Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.Proc Natl Acad Sci U S A2003https://conductscience.org/library/papers/12890867PubMed
1816857985A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.Blood2006https://conductscience.org/library/papers/16857985PubMed
1917016430A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.Oncogene2007https://conductscience.org/library/papers/17016430PubMed
2015459012A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.Blood2005https://conductscience.org/library/papers/15459012PubMed

See all 47 referencesDownload CSV of references

Cited by50

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
42630653Targeting FLT3 in Acute Myeloid Leukemia: Structural Insights and Key Challenges.ACS Bio Med Chem Au2026https://conductscience.org/library/papers/42630653PubMed
41942459Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.Nat Commun2026https://conductscience.org/library/papers/41942459PubMed
41937490Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC.J Cell Mol Med2026https://conductscience.org/library/papers/41937490PubMed
38112995FLT3 targeting in the modern era: from clonal selection to combination therapies.Int J Hematol2024https://conductscience.org/library/papers/38112995PubMed
38007585TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.Leukemia2024https://conductscience.org/library/papers/38007585PubMed
37958832AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.Int J Mol Sci2023https://conductscience.org/library/papers/37958832PubMed
37760544Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37760544PubMed
36293564Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.Int J Mol Sci2022https://conductscience.org/library/papers/36293564PubMed
36185253Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.Front Oncol2022https://conductscience.org/library/papers/36185253PubMed
35565314Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.Cancers (Basel)2022https://conductscience.org/library/papers/35565314PubMed
35417742Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia.Exp Hematol2022https://conductscience.org/library/papers/35417742PubMed
34203664Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia.Antioxidants (Basel)2021https://conductscience.org/library/papers/34203664PubMed
33598693Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.Blood2021https://conductscience.org/library/papers/33598693PubMed
33425766FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.Front Oncol2020https://conductscience.org/library/papers/33425766PubMed
33121874Extinguishing the Embers: Targeting AML Metabolism.Trends Mol Med2021https://conductscience.org/library/papers/33121874PubMed
32722298Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Biomedicines2020https://conductscience.org/library/papers/32722298PubMed
31717784Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.Cancers (Basel)2019https://conductscience.org/library/papers/31717784PubMed
31632141Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.Cancer Manag Res2019https://conductscience.org/library/papers/31632141PubMed
30972300The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome.Front Oncol2019https://conductscience.org/library/papers/30972300PubMed
30800259Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.Ther Adv Hematol2019https://conductscience.org/library/papers/30800259PubMed

See all 50 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
MCL14170PubTator's text mininghttps://conductscience.org/library/genes/4170NCBI Gene
STAT5A6776PubTator's text mininghttps://conductscience.org/library/genes/6776NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17554384

GET https://conductscience.org/api/papers/v1/17554384/references?page=2